184 results on '"Martinez-Hernandez, Eugenia"'
Search Results
2. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study
3. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
4. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
5. Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders
6. Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom
7. CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD: Clinical and Immunologic Follow-Up for 1 Year.
8. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study
9. Neural signatures of reduced serial dependence in anti-NMDAR encephalitis and schizophrenia
10. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study
11. Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy
12. Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease
13. MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
14. Blocking Placental Class G Immunoglobulin Transfer Prevents NMDA Receptor Antibody Effects in Newborn Mice
15. Thymoma and Autoimmune Encephalitis: Clinical Manifestations and Antibodies
16. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis
17. Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies
18. Author Response: Clinical Significance of Anti-NMDAR Concurrent With Glial or Neuronal Surface Antibodies
19. 33 Autoimmune encephalitis
20. Frequency and Referral Patterns of Neural Antibody Studies During the COVID-19 Pandemic
21. Reduced serial dependence suggests deficits in synaptic potentiation in anti-NMDAR encephalitis and schizophrenia
22. Sleep disorders in anti-NMDAR encephalitis
23. Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders (S22.006)
24. Clinical characterization and outcome of 47 patients with neurologic adverse events of immune-checkpoint inhibitors (P4-5.026)
25. Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus
26. Post-mortem neuropathologic examination of a 5-case series of CAR T-cell treated patients
27. Post-mortem neuropathologic examination of a 6-case series of CAR T-cell treated patients
28. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma
29. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes
30. Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy
31. Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy
32. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events:population based cohort and self-controlled case series analysis
33. Telemedicine for Monitoring MS Activity and Progression
34. Encephalitis with Autoantibodies against the Glutamate Kainate Receptor (GluK2) (S41.002)
35. Neurofilament light chain levels in anti-NMDAR encephalitis and primary psychiatric psychosis (S41.005)
36. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis
37. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID ‐19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries
38. “Association between COVID-19 vaccination, infection, and risk of Guillain-Barre syndrome, Bell’s palsy, encephalomyelitis and transverse myelitis: a population-based cohort and self-controlled case series analysis”
39. Antibodies to Aquaporin 4, Myelin-Oligodendrocyte Glycoprotein, and the Glycine Receptor α1 Subunit in Patients With Isolated Optic Neuritis
40. Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2: a population-based cohort analysis
41. Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis
42. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
43. Thymoma and Autoimmune Encephalitis
44. Guillain-Barr�� syndrome after SARS-CoV-2 infection in an international prospective cohort study
45. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study
46. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study
47. Autoimmune Septin-5 Disease Presenting as Spinocerebellar Ataxia and Nystagmus
48. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 25.4 million people in six European countries
49. Seizure-related 6 homolog like 2 (SEZ6L2) autoimmunity: Neurologic syndrome and antibody effects (1802)
50. Incidence and impact of COVID-19 in a cohort of patients with myasthenia gravis from Barcelona. (4170)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.